Mizoribine selectively attenuates monocyte chemoattractant protein-1 production in cultured human glomerular mesangial cell: a possible benefit of its use in the treatment of lupus nephritis.
about
Mizoribine in the treatment of pediatric-onset glomerular disease.Post-marketing surveillance study of the long-term use of mizoribine for the treatment of lupus nephritis: 2-Year results.Treatment of pediatric-onset lupus nephritis: a proposal of optimal therapy.Toll-like receptor 3 signaling contributes to the expression of a neutrophil chemoattractant, CXCL1 in human mesangial cells.
P2860
Mizoribine selectively attenuates monocyte chemoattractant protein-1 production in cultured human glomerular mesangial cell: a possible benefit of its use in the treatment of lupus nephritis.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Mizoribine selectively attenua ...... treatment of lupus nephritis.
@en
Mizoribine selectively attenua ...... treatment of lupus nephritis.
@nl
type
label
Mizoribine selectively attenua ...... treatment of lupus nephritis.
@en
Mizoribine selectively attenua ...... treatment of lupus nephritis.
@nl
prefLabel
Mizoribine selectively attenua ...... treatment of lupus nephritis.
@en
Mizoribine selectively attenua ...... treatment of lupus nephritis.
@nl
P2093
P2860
P356
P1433
P1476
Mizoribine selectively attenua ...... treatment of lupus nephritis.
@en
P2093
Hidemi Yoshida
Kazushi Tsuruga
Shojiro Watanabe
Tadaatsu Imaizumi
Tomoh Matsumiya
Tomomi Aizawa
Yuki Chiba
P2860
P356
10.1111/NEP.12171
P50
P577
2014-01-01T00:00:00Z